November 22, 2024
On November 22, 2024, Sungen Biomedical won "2024 Top 10 Innovative Pharmaceutical Enterprises" selected by China Times
On November 22, 2024, Sungen Biomedical won "2024 Top 10 Innovative Pharmaceutical Enterprises" selected by China Times
On November 19, 2024, Sungen Biomedical won the first prize of Beijing Science and Technology Progress Award 2023
On September 27, 2024, Sungen Biomedical won the Ernst & Young Fudan Most Promising Enterprise Award 2024
On August 05, 2024, Sungen Biomedical SGC001 injection obtained the clinical trial implied approval from Center for Drug Evaluation, National Medical Products Administration.
On May 23, 2024 (US time), clinical trial application (IND) of the world's first innovative drug SGC001 developed by Beijing Sungen Biomedical was approved by the US Food and Drug Administration (FDA).
In February 2024, SGC001 project completed CMC study and non-clinical safety evaluation, and submitted the pre-IND application in China and the United States.
On November 20, 2023, Beijing Antai Institute of Cardiovascular Medicine and Beijing Sungen Biomedical Technology Co., LTD. established the "Joint Laboratory of Cardiovascular Disease Biological Innovation Drug Research and Development Center".
On October 31, 2023, Shenzhen Zhiyuan Biomedical Co., LTD. and Beijing Sungen Biomedical Technology Co., LTD. set up the "National Human Brain Health project" joint laboratory.
On December 15, 2022, Sungen Biomedical's SGC001 project entered the CMC phase;
In November 2022, Sungen Biomedical obtained the qualification of Zhongguancun High-tech Enterprise;
In October 2021, Sungen Biomedical obtained the qualification of High-tech enterprise;
On December 21, 2018, Sungen Biomedical was established in Beijing, China. Professor Sun Zhiwei's research team started the development of antibody drugs of innovative targets.
